CD105/Endoglin (3A9) Mouse mAb #14606
- WB
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 95 |
| Source/Isotype | Mouse IgG1 |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:400 - 1:1600 |
Storage
For a carrier free (BSA and azide free) version of this product see product #37995.
Protocol
Specificity / Sensitivity
CD105/Endoglin (3A9) Mouse mAb recognizes endogenous levels of total CD105/Endoglin protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with purified recombinant fragment of human CD105/Endoglin expressed in E. Coli.
Background
CD105/Endoglin is an auxiliary receptor for the TGF-β receptor complex, functioning in related signaling pathways (1,2). CD105/Endoglin is a transmembrane protein that exists as a disulfide-linked homodimer. It is mainly expressed in vascular and connective tissues and in endothelial and stromal cells. Upregulated CD105/endoglin expression has been reported during wound healing and tumor vascularization, and in inflammatory tissues and developing embryos (1-4). Mutations inCD105/endoglin have been found to be a causal factor of hereditary hemorrhagic telangiectasia (HHT), a disease characterized by malformation of vascular structure (5,6). The importance of this protein for normal and tumor vascular function makes it a good marker for endothelial cell proliferation as well as a potential therapeutic target in cancer (4-6).
- Bernabeu, C. et al. (2007) J Cell Biochem 102, 1375-88.
- Zhu, Y. et al. (2003) Stroke 34, 2483-8.
- Quintanilla, M. et al. (2003) Oncogene 22, 5976-85.
- Dallas, N.A. et al. (2008) Clin Cancer Res 14, 1931-7.
- ten Dijke, P. et al. (2008) Angiogenesis 11, 79-89.
- Fernández-L, A. et al. (2006) Clin Med Res 4, 66-78.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.